Ferroptosis Regulator Information
General Information of the Ferroptosis Regulator (ID: REG10388)
Full List of the Ferroptosis Target of This Regulator and Corresponding Disease/Drug Response(s)
IGF1R
can regulate the following target(s), and cause disease/drug response(s). You can browse detail information of target(s) or disease/drug response(s).
Browse Target
Browse Disease
Browse Drug
Unspecific Target [Unspecific Target]
In total 1 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis Target of This Regulator | [1] | ||||
Responsed Disease | Melanoma | ICD-11: 2C30 | |||
Responsed Drug | Lorlatinib | Investigative | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
PI3K-Akt signaling pathway | hsa04151 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model |
SK-MEL-28 cells | Cutaneous melanoma | Homo sapiens | CVCL_0526 | |
A-375 cells | Amelanotic melanoma | Homo sapiens | CVCL_0132 | ||
WM35 cells | Melanoma | Homo sapiens | CVCL_0580 | ||
SK-MEL-5 cells | Cutaneous melanoma | Homo sapiens | CVCL_0527 | ||
786-O cells | Renal cell carcinoma | Homo sapiens | CVCL_1051 | ||
Caki-1 cells | Clear cell renal cell carcinoma | Homo sapiens | CVCL_0234 | ||
MDA-MB-231 cells | Breast adenocarcinoma | Homo sapiens | CVCL_0062 | ||
HEK-293T cells | Normal | Homo sapiens | CVCL_0063 | ||
In Vivo Model |
All animal experiments were approved by the Ethical Review of Experimental Animals at Central South University. To generate subcutaneous tumors, 2 x 106 control A375 cells or GPX4 KO cells were suspended in 100 ul PBS and injected subcutaneously into nude mice (Shanghai SLAC). Tumor-bearing mice were randomly allocated into groups and treated with vehicle (2% DMSO + 30% PEG300, per day by orally) or lorlatinib (10 mg/kg, per day by orally). Liproxstatin-1 (10 mg/kg) was administrated through intraperitoneal injection per day. Tumors were weighted and photographed on day 18 after treatment. Tumor size were recorded every three days and calculated as [(length x width x width)/2].
Click to Show/Hide
|
||||
Response regulation | Lorlatinib sensitized melanoma to ferroptosis through targeting IGF1R-mediated PI3K/AKT/mTOR signaling axis and its downstream SCD expression. | ||||
Melanoma [ICD-11: 2C30]
In total 1 item(s) under this disease | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response | [1] | ||||
Target Regulator | Insulin-like growth factor 1 receptor (IGF1R) | Protein coding | |||
Responsed Drug | Lorlatinib | Investigative | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
PI3K-Akt signaling pathway | hsa04151 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model |
SK-MEL-28 cells | Cutaneous melanoma | Homo sapiens | CVCL_0526 | |
A-375 cells | Amelanotic melanoma | Homo sapiens | CVCL_0132 | ||
WM35 cells | Melanoma | Homo sapiens | CVCL_0580 | ||
SK-MEL-5 cells | Cutaneous melanoma | Homo sapiens | CVCL_0527 | ||
786-O cells | Renal cell carcinoma | Homo sapiens | CVCL_1051 | ||
Caki-1 cells | Clear cell renal cell carcinoma | Homo sapiens | CVCL_0234 | ||
MDA-MB-231 cells | Breast adenocarcinoma | Homo sapiens | CVCL_0062 | ||
HEK-293T cells | Normal | Homo sapiens | CVCL_0063 | ||
In Vivo Model |
All animal experiments were approved by the Ethical Review of Experimental Animals at Central South University. To generate subcutaneous tumors, 2 x 106 control A375 cells or GPX4 KO cells were suspended in 100 ul PBS and injected subcutaneously into nude mice (Shanghai SLAC). Tumor-bearing mice were randomly allocated into groups and treated with vehicle (2% DMSO + 30% PEG300, per day by orally) or lorlatinib (10 mg/kg, per day by orally). Liproxstatin-1 (10 mg/kg) was administrated through intraperitoneal injection per day. Tumors were weighted and photographed on day 18 after treatment. Tumor size were recorded every three days and calculated as [(length x width x width)/2].
Click to Show/Hide
|
||||
Response regulation | Lorlatinib sensitized melanoma to ferroptosis through targeting IGF1R-mediated PI3K/AKT/mTOR signaling axis and its downstream SCD expression. | ||||
Lorlatinib
[Investigative]
In total 1 item(s) under this drug | |||||
Experiment 1 Reporting the Ferroptosis-centered Drug Response | [1] | ||||
Drug for Ferroptosis | Inducer | ||||
Response Target | Unspecific Target | ||||
Responsed Disease | Melanoma | ICD-11: 2C30 | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
PI3K-Akt signaling pathway | hsa04151 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model |
SK-MEL-28 cells | Cutaneous melanoma | Homo sapiens | CVCL_0526 | |
A-375 cells | Amelanotic melanoma | Homo sapiens | CVCL_0132 | ||
WM35 cells | Melanoma | Homo sapiens | CVCL_0580 | ||
SK-MEL-5 cells | Cutaneous melanoma | Homo sapiens | CVCL_0527 | ||
786-O cells | Renal cell carcinoma | Homo sapiens | CVCL_1051 | ||
Caki-1 cells | Clear cell renal cell carcinoma | Homo sapiens | CVCL_0234 | ||
MDA-MB-231 cells | Breast adenocarcinoma | Homo sapiens | CVCL_0062 | ||
HEK-293T cells | Normal | Homo sapiens | CVCL_0063 | ||
In Vivo Model |
All animal experiments were approved by the Ethical Review of Experimental Animals at Central South University. To generate subcutaneous tumors, 2 x 106 control A375 cells or GPX4 KO cells were suspended in 100 ul PBS and injected subcutaneously into nude mice (Shanghai SLAC). Tumor-bearing mice were randomly allocated into groups and treated with vehicle (2% DMSO + 30% PEG300, per day by orally) or lorlatinib (10 mg/kg, per day by orally). Liproxstatin-1 (10 mg/kg) was administrated through intraperitoneal injection per day. Tumors were weighted and photographed on day 18 after treatment. Tumor size were recorded every three days and calculated as [(length x width x width)/2].
Click to Show/Hide
|
||||
Response regulation | Lorlatinib sensitized melanoma to ferroptosis through targeting IGF1R-mediated PI3K/AKT/mTOR signaling axis and its downstream SCD expression. | ||||